ES2385251A1 - Adenovirus oncolíticos para el tratamiento del cáncer. - Google Patents

Adenovirus oncolíticos para el tratamiento del cáncer. Download PDF

Info

Publication number
ES2385251A1
ES2385251A1 ES200901201A ES200901201A ES2385251A1 ES 2385251 A1 ES2385251 A1 ES 2385251A1 ES 200901201 A ES200901201 A ES 200901201A ES 200901201 A ES200901201 A ES 200901201A ES 2385251 A1 ES2385251 A1 ES 2385251A1
Authority
ES
Spain
Prior art keywords
art
oncolytic
adenovirus
cancer
vol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200901201A
Other languages
English (en)
Other versions
ES2385251B1 (es
Inventor
Sònia Guedán Carrió
Manel María Cascalló Piqueras
Ramón Alemany Bonastre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut D Investigacio Biomedica De Bell
Original Assignee
Institut d'Investigació Biomédica de Bellvitge
Institut Català d'Oncologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2385251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia filed Critical Institut d'Investigació Biomédica de Bellvitge
Priority to ES200901201A priority Critical patent/ES2385251B1/es
Priority to JP2012509064A priority patent/JP2012525833A/ja
Priority to CN201080028895XA priority patent/CN102548584A/zh
Priority to ES10772050T priority patent/ES2600955T5/es
Priority to CN201710271203.8A priority patent/CN107252438A/zh
Priority to CA2761183A priority patent/CA2761183C/en
Priority to RU2011149458/10A priority patent/RU2536931C2/ru
Priority to HK12108533.3A priority patent/HK1167818B/en
Priority to FIEP10772050.0T priority patent/FI2428229T4/fi
Priority to MX2011011818A priority patent/MX2011011818A/es
Priority to US13/318,876 priority patent/US10316065B2/en
Priority to AU2010244348A priority patent/AU2010244348B2/en
Priority to PL10772050.0T priority patent/PL2428229T5/pl
Priority to BRPI1011445A priority patent/BRPI1011445B8/pt
Priority to EP10772050.0A priority patent/EP2428229B2/en
Priority to PCT/ES2010/000196 priority patent/WO2010128182A1/es
Priority to KR1020117029097A priority patent/KR101878274B1/ko
Publication of ES2385251A1 publication Critical patent/ES2385251A1/es
Publication of ES2385251B1 publication Critical patent/ES2385251B1/es
Application granted granted Critical
Priority to HK18104062.5A priority patent/HK1244679A1/zh
Priority to US16/405,285 priority patent/US12129280B2/en
Priority to US18/774,209 priority patent/US20250011373A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Adenovirus oncolíticos para el tratamiento del cáncer.La invención se refiere a un adenovirus oncolítico que comprende una secuencia que codifica una enzima hialuronidasa insertada en su genoma. Este adenovirus se distribuye más eficientemente por la masa tumoral y por consiguiente se aumenta el efecto oncolítico. Inyectando el adenovirus oncolítico de la invención endovenosamente se obtienen regresiones del volumen tumoral. Por lo tanto el adenovirus oncolítico de la presente invención es útil para el tratamiento del cáncer o de un estado pre-maligno del mismo.

Claims (2)

  1. REIVINDICACIONES
    1
    OFICINA ES ANOLA DE ATENTES Y MARCAS
    N.° solicitud:
    ES ANA
    Fecha de presentaci6n de la solicitud: 6. .
    3 Fecha de prioridad:
    INFORME SOBRE EL ESTADO DE LA TECNICA
    Int. Cl. : C12N151861 ( 6. ) A61K48100 ( 6. )
    DOCUMENTOS RELEVANTES
    Categoria
    ® Documentos citados Reivindicaciones afectadas
    Y Y Y Y Y GANESH S. et al.: "Relaxin� espressing fiber chimeric oncolytic adenovirus prolongs survival of tumor�bearingmice', CANCER RES, ( 7), vol. 67, no. , 7, paginas 43 �44 7, todo el documento. KIM JO O�HANG et al .: "Relaxin e xpression f rom t umor�targeting ade noviruses and its intratumoral spread, apoptosis induction, and efficacy", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY RESS, GB, ( 6), vol 8, n° , pag. 48 � 4 3, todo el documento. GANESH S.: "Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models", ( 8), CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, n° , pag. 3 33� 3 4 , todo el documento. JIN CHENG et al.: "Human Matrix Metalloproteinase 8 Gene Delivery increases the Oncolytic Activityof a Replicating Adenovirus", ( 7), MOLECULAR THERA Y, vol. �, n° , pag. 8 � , todo el documento. TOOLE B et al.: "Hyaluronan; A constitutive regulator of chemoresistance and malignancyin cancer cells", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC UBLICATIONS, HILADEL HIA, A, US, ( 8), vol. 8, n° 4, pag. 44� � , todo el documento.
    Categoria de los documentos citados X: de particular relevancia Y: de particular relevancia combinado con otro/s de la misma categoria A: refleja el estado de la tecnica O: referido a divulgaci6n no escrita : publicado entre la fecha de prioridad yla de presentaci6n de la solicitud E: documento anterior, pero publicado despues de la fecha de presentaci6n de la solicitud
    El presente informe ha sido realizado � para todas las reivindicaciones � para las reivindicaciones n°:
    Fecha de realizaci6n del informe 3. 7. Examinador M. Hernandez Cuellar Pagina /4
    INFORME DEL ESTADO DE LA TECNICA
    N° de solicitud:
    Documentaci6n minima buscada (sistema de clasificaci6n seguido de los simbolos de clasificaci6n) C N, A6 K Bases de datos electr6nicas consultadas durante la busqueda (nombre de la base de datos y, si es posible, terminos de
    busqueda utilizados) E ODOC, W I, MEDLINE, EMBASE, BIOSIS, CA LUS
    Informe del Estado de la Tecnica agina /4
    OPINION ESCRITA
    N° de solicitud:
    Fecha de Realizaci6n de la Opini6n Escrita: 3. 7.
    Declaraci6n
    Novedad (Art. .1 LP 11/198 ) Reivindicaciones SI Reivindicaciones NO
    Actividad inventiva (Art. 8.1 LP11/198 ) Reivindicaciones SI Reivindicaciones NO
    Se considera que la solicitud cumple con el requisito de aplicaci6n industrial. Este requisito fue evaluado durante la fase de examen formal y tecnico de la solicitud (Articulo 3 . Ley / 86).
    Base de la Opini6n.-
    La presente opini6n se ha realizado sobre la base de la solicitud de patente tal y como se publica.
    Informe del Estado de la Tecnica agina 3/4
    OPINION ESCRITA
    N° de solicitud:
    1. Documentos considerados.-
    A continuaci6n se relacionan los documentos pertenecientes al estado de la tecnica tomados en consideraci6n para la realizaci6n de esta opini6n.
    Documento
    Numero Publicaci6n o Identificaci6n Fecha Publicaci6n
    D
    GANESH S. et al.: "Relaxin� espressing fiber chimeric oncolytic adenovirus prolongs survival of tumor �bearing mice', CANCER RES, ( 7), vol. 67, n o. , 7, paginas 43 �44 7, todo el documento.
    D
    KIM JOO�HANG et al.: "Relaxin expression from tumor�targeting adenoviruses and i ts intratumoral sp read, apoptosis induction, and ef ficacy", JO URNAL O F THE NATIONAL CA NCER INSTITUTE, OXFORD UNIVERSITY RESS, GB, ( 6), vol 8, n° , pag. 48 � 4 3, todo el documento.
    D 3
    GANESH S.: "Intratumoral coadministration of hyaluronidase enzyme an d oncolytic adenoviruses enhances virus potency i n metastatic tumor m odels", ( 8), C LINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, n° , pag. 3 33� 3 4 , todo el documento.
    D 4
    JIN CHE NG et al .: "H uman Ma trix Metalloproteinase�8 Gene Delivery i ncreases the O ncolytic Activity of a R eplicating Adenovirus", ( 7), MO LECULAR T HERA Y, vol. �, n° , pag. 8 � , todo el documento.
    D �
    TOOLE B et al.: "Hyaluronan; A constitutive regulator of chemoresistance and malignancy in cancer cells", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC UBLICATIONS, HILADEL HIA, A, US, ( 8), vol. 8, n° 4, pag. 44�� , todo el documento.
  2. 2. Declaraci6n motivada segun los articulos 29. y 29.7 del Reglamento de ejecuci6n de la Ley 11/198 , de 20 de marzo, de Patentes sobre la novedad y la actividad inventiva; citas y explicaciones en apoyo de esta declaraci6n
    La presente invenci6n se refiere a adenovirus oncoliticos que tienen una secuencia que codifica una hialuronidasa insertada en su genoma, asi como a composiciones farmaceuticas que comprenden el citado adenovirus y su uso para la fabricaci6n de un medicamento para el tratamiento del cancer.
    .� NOVEDAD Ninguno de los documentos citados describe adenovirus oncoliticos que tienen una secuencia que codifica una hialuronidasa insertada e n s u ge noma. E n co nsecuencia l as reivindicaciones cumplen e l r equisito de nov edad establecido en el Art. 6. L / 86.
    .�ACTIVIDAD INVENTIVA Cualquiera de los documentos D y D se puede considerar representativo del estado de la tecnica mas cercano a la invenci6n. Ambos documentos describen un adenovirus oncolitico que comprende una secuencia que codifica relaxina insertada en su genoma. La diferencia entre la informaci6n aportada en ambos documentos y la reivindicaci6n es la elecci6n de la hialuronidasa como el gen expresado por el adenovirus oncolitico. El efecto de esta diferencia es el mismoque el mostrado en ambos documentos, es decir, la degradaci6n de la matriz extracelular de las celulas tumorales para facilitar la diseminaci6n del adenovirus y mejorar su eficacia. El problema subyacente de la reivindicaci6n se puede plantear como la provisi6n de un adenovirus oncolitico alternativo con el mismo prop6sito. La soluci6n que proporciona la reivindicaci6n es un adenovirus oncolitico que tienen una secuencia que codifica una hialuronidasa insertada en su genoma. El documento D � describe la capacidad de la hialuronidasa para degradar la matriz extracelular de las celulas tumorales y permitir una diseminaci6n eficiente de los adenovirus oncoliticos que mejora la actividad anti tumoral, tal y como se describe en D 3. En este sentido se considera que la capacidad de degradar la matriz extracelular asi como su posible uso para mejorar la diseminaci6n y eficacia de un adenovirus oncolitico era informaci6n accesible para un experto en la materia con anterioridad la presentaci6n de la solicitud de patente. A la vista de la mejora proporcionada por la expresi6n de una enzima que degrada la matriz extracelular por el adenovirus oncolitico en vez de la coadministraci6n de la hialuronidasa con el adenovirus oncolitico, el experto en la materia habria conseguido el objeto de la reivindicaci6n sin esfuerzo inventivo. Las reivindicaciones dependientes tambien carecen de actividad inventiva ya que corresponden a realizaciones que se consideran rutinarias en el estado de la tecnica. Finalmente, losadenovirus oncoliticos descritos en el estado de la tecnica se usan para el tratamiento del cancer. En este sentido, los usos terapeuticos de las reivindicaciones y tambien carecen de actividad inventiva. En consecuencia, las reivindicaciones no cumplen el requisito establecido en el Art. 8. L / 86.
    Informe del Estado de la Tecnica agina 4/4
ES200901201A 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer. Expired - Fee Related ES2385251B1 (es)

Priority Applications (20)

Application Number Priority Date Filing Date Title
ES200901201A ES2385251B1 (es) 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer.
US13/318,876 US10316065B2 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
PL10772050.0T PL2428229T5 (pl) 2009-05-06 2010-05-05 Onkolityczne adenowirusy do leczenia raka
ES10772050T ES2600955T5 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
CN201710271203.8A CN107252438A (zh) 2009-05-06 2010-05-05 用于治疗癌症的溶瘤腺病毒
CA2761183A CA2761183C (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
RU2011149458/10A RU2536931C2 (ru) 2009-05-06 2010-05-05 Онколитический аденовирус для лечения рака, его применение и фармацевтическая композиция, содержащая его
HK12108533.3A HK1167818B (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
FIEP10772050.0T FI2428229T4 (fi) 2009-05-06 2010-05-05 Onkolyyttisiä adenoviruksia syövän hoitoon
MX2011011818A MX2011011818A (es) 2009-05-06 2010-05-05 Adenovirus oncoliticos para el tratamiento del cancer.
JP2012509064A JP2012525833A (ja) 2009-05-06 2010-05-05 癌治療のための腫瘍溶解アデノウイルス
AU2010244348A AU2010244348B2 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
CN201080028895XA CN102548584A (zh) 2009-05-06 2010-05-05 用于治疗癌症的溶瘤腺病毒
BRPI1011445A BRPI1011445B8 (pt) 2009-05-06 2010-05-05 Adenovírus oncolíticos para o tratamento de câncer
EP10772050.0A EP2428229B2 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
PCT/ES2010/000196 WO2010128182A1 (es) 2009-05-06 2010-05-05 Adenovirus oncolíticos para el tratamiento del cáncer
KR1020117029097A KR101878274B1 (ko) 2009-05-06 2010-05-05 암 치료용 암 용해성 아데노바이러스
HK18104062.5A HK1244679A1 (zh) 2009-05-06 2018-03-23 用於治疗癌症的溶瘤腺病毒
US16/405,285 US12129280B2 (en) 2009-05-06 2019-05-07 Oncolytic adenoviruses for treating cancer
US18/774,209 US20250011373A1 (en) 2009-05-06 2024-07-16 Oncolytic adenoviruses for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200901201A ES2385251B1 (es) 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer.

Publications (2)

Publication Number Publication Date
ES2385251A1 true ES2385251A1 (es) 2012-07-20
ES2385251B1 ES2385251B1 (es) 2013-05-06

Family

ID=43050014

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200901201A Expired - Fee Related ES2385251B1 (es) 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer.
ES10772050T Active ES2600955T5 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10772050T Active ES2600955T5 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer

Country Status (15)

Country Link
US (3) US10316065B2 (es)
EP (1) EP2428229B2 (es)
JP (1) JP2012525833A (es)
KR (1) KR101878274B1 (es)
CN (2) CN107252438A (es)
AU (1) AU2010244348B2 (es)
BR (1) BRPI1011445B8 (es)
CA (1) CA2761183C (es)
ES (2) ES2385251B1 (es)
FI (1) FI2428229T4 (es)
HK (1) HK1244679A1 (es)
MX (1) MX2011011818A (es)
PL (1) PL2428229T5 (es)
RU (1) RU2536931C2 (es)
WO (1) WO2010128182A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
CN103405480B (zh) * 2013-05-03 2015-11-25 浙江理工大学 10-羟基喜树碱-丁二酸与腺病毒结合物及制法和用途
CN103614416B (zh) * 2013-09-30 2016-09-07 中国人民解放军第二军医大学东方肝胆外科医院 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
KR102272932B1 (ko) * 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
AU2015332533B2 (en) 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein
CN107849111B (zh) * 2015-05-04 2022-02-22 Vcn生物科学有限公司 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途
CN104946601A (zh) * 2015-05-28 2015-09-30 金宁一 重组溶瘤腺病毒及其应用
US11155622B2 (en) 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR102323872B1 (ko) * 2016-04-22 2021-11-08 임비라 컴퍼니 리미티드 암치료용 종양 용해성 단순 헤르페스 바이러스(oHSV) 절대 벡터 및 그 구조체의 구조
KR20240011868A (ko) * 2016-04-29 2024-01-26 이노비오 파마수티컬즈, 인크. 제제의 전달을 향상시키기 위한 콘드로이티나제 및/또는 히알루로니다제의 생체내 용도
WO2017201635A1 (zh) * 2016-05-23 2017-11-30 蔡胜和 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用
EP3478321A4 (en) * 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
KR102491752B1 (ko) 2016-08-29 2023-01-26 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CN109982709A (zh) * 2016-11-17 2019-07-05 Vcn生物科学有限公司 病毒载体在治疗视网膜母细胞瘤中的用途
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
EP3708657A4 (en) 2017-11-08 2021-08-25 Kagoshima University ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) THAT IS CAPABLE OF TREATING METASTATIC CANCER ALSO WITH ENSURED SAFETY, WITH EXPRESSION CONTROL SYSTEM THAT BUILDS AN OPTIMAL EXPRESSION LEVEL
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
CN109913422A (zh) * 2017-12-13 2019-06-21 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
AU2019208892B2 (en) * 2018-01-19 2022-02-03 Kolon Life Science, Inc. Recombinant vaccinia virus and pharmaceutical composition comprising same
WO2019174610A1 (zh) * 2018-03-14 2019-09-19 蔡立刚 一种溶瘤病毒、合成dna序列及其应用
EP3773649A4 (en) 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
KR20220038485A (ko) 2019-08-05 2022-03-28 메조블라스트 인터내셔널 에스에이알엘 바이러스 벡터를 포함하는 세포 조성물 및 치료 방법
TW202615652A (zh) 2020-01-23 2026-04-16 南韓商阿特根公司 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法
WO2022031093A1 (ko) 2020-08-07 2022-02-10 (주)알테오젠 재조합 히알루로니다제의 생산 방법
CN115996735A (zh) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 细胞组合物和治疗方法
RU2753742C1 (ru) * 2020-10-16 2021-08-24 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Рекомбинантный штамм Ad6-hTERT-GMCSF, содержащий встройку промотора теломеразы человека hTERT, а также гена гранулоцитарно-макрофагального колониестимулирующего фактора человека, обладающий избирательной цитолитической активностью против теломераза-положительных опухолевых клеток и экспрессирующий активный человеческий гранулоцитарно-макрофагальный колониестимулирующий фактор
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
CN114703186B (zh) * 2022-03-31 2023-08-29 四川大学 肿瘤特异性启动子及其应用
CN117379389B (zh) * 2022-07-12 2026-03-06 四川大学 血小板-溶瘤病毒复合物、其制备方法及其应用
WO2024062372A1 (en) * 2022-09-19 2024-03-28 Theriva Biologics, S.L. Combination therapies with oncolytic adenovirus and topoisomerase i inhibitors or prodrugs thereof
JP2025536260A (ja) 2022-10-11 2025-11-05 イェール ユニバーシティー 細胞透過性抗体の組成物および使用方法
KR20260077739A (ko) * 2023-09-20 2026-05-28 테리바 바이오로직스 에스.엘. 암의 치료에 사용하기 위한 종양용해성 아데노바이러스와 토포아이소머라제 i 저해제

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
EP0872552A1 (en) 1997-04-15 1998-10-21 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin
US5516631A (en) 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
DK0689447T3 (da) 1993-02-16 1999-10-18 Onyx Pharma Inc Cytopatiske vira til behandling af og profylakse for neoplasia
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US20040048821A1 (en) 1997-06-27 2004-03-11 Cold Spring Harbor Laboratory Enhancement of drug cytotoxicity in tumor cells containing mutant Rb gene
CN1304316A (zh) 1998-02-06 2001-07-18 亚拉巴马大学伯明翰分校研究基金会 在纤维结的hi环中含有异源肽表位的腺病毒载体
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
CZ301506B6 (cs) 1998-10-15 2010-03-31 Canji, Inc. Selektivne se replikující rekombinantní virový vektor a zpusob jeho prípravy, farmaceutická formulace, zpusob usmrcení bunky s defektní dráhou, transformovaná bunka a promotor reagující na dráhu p53 a TGF-ß
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
WO2000029599A1 (en) 1998-11-18 2000-05-25 Canji, Inc. Viral vectors with late transgene expression
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
EP1180932B1 (en) 1999-05-12 2012-01-11 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
US7078030B2 (en) 1999-11-15 2006-07-18 Onyx Pharmaceuticals, Inc Oncolytic adenovirus
WO2001036650A2 (en) 1999-11-15 2001-05-25 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
US20020164715A1 (en) 2000-07-10 2002-11-07 Lin Ji Chromosome 3p21.3 genes are tumor suppressors
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
CA2439185A1 (en) 2001-02-23 2002-09-06 Novartis Ag Vector constructs
NZ527687A (en) 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
EP1516055A4 (en) 2002-01-24 2007-08-08 Scripps Research Inst FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
AU2003241268A1 (en) 2002-02-05 2003-09-09 Cornell Research Foundation, Inc. Adenoviral vector with replication-dependent transgene expression
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
AU2003220115A1 (en) 2002-05-20 2003-12-12 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2519680A1 (en) * 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
WO2005018332A1 (en) * 2003-08-13 2005-03-03 The General Hospital Corporation Modified microorganisms for anti-cancer therapy
US20070036721A1 (en) * 2003-09-23 2007-02-15 Uab Resarch Foundation Methods and compositions for in vivo inflammation monitoring
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
US8658778B2 (en) 2005-03-09 2014-02-25 Board Of Regents, The University Of Texas System hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
WO2007059473A2 (en) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
ATE516370T1 (de) 2005-12-22 2011-07-15 Sloan Kettering Inst Cancer Verfahren zur erfassung von krebszellen unter verwendung eines virus
CN101970650B (zh) * 2008-03-06 2017-07-25 哈洛齐梅公司 可溶性透明质酸酶的大规模生产
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
BR112020015488A2 (pt) * 2018-02-08 2020-12-08 Sangamo Therapeutics, Inc. Nucleases alvo-específicas modificadas

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GANESH S,: ¿Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenovíruses enhances virus potency in metastatic tumor models¿, (2008), CL1NICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, nº 12, pág. 3933-3941, todo el documento. *
GANESH S. ET AL: ¿Relaxin- espressing fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice¿, CANCER RES, (2007), vol. 67, no. 9, 2007, pages 4399-4407, todo el documento. *
JIN CHENG ET AL: ¿Human Matrix Metalloproteinase-8 Gene Delivery increases the Oncolytic Activity of a Replicating Adenovirus¿, (2007), MOLECULAR THERAPY, vol.. 15, nº 11, pág. 1982-1990, todo el documento. *
KIM JOO- HANG ET AL; ¿Relaxin expression from tumor- targetíng adenoviruses and its intratumoral spread, apoptosís induction, and efficacy¿, JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, ( 2006), vol 98, nº 20, 1 pág. 1482-1493, todo el documento. *
TOOLE B P ET AL: ¿Hyaluronan; A constitutive regulator of chemoresistance and malignancy in cancer cells¿, SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC PUBLICATIONS, PHILADELPHTA, PA, US, (2008), vol. 18, nº 4, pág. 244-250, todo el documento. *

Also Published As

Publication number Publication date
HK1167818A1 (en) 2012-12-14
CA2761183A1 (en) 2010-11-11
EP2428229B2 (en) 2025-05-21
PL2428229T3 (pl) 2017-02-28
US20190345204A1 (en) 2019-11-14
MX2011011818A (es) 2012-06-19
BRPI1011445B1 (pt) 2022-10-04
BRPI1011445B8 (pt) 2022-10-25
US20250011373A1 (en) 2025-01-09
WO2010128182A1 (es) 2010-11-11
KR20120049185A (ko) 2012-05-16
AU2010244348A1 (en) 2011-12-01
KR101878274B1 (ko) 2018-07-13
BRPI1011445A2 (pt) 2020-09-15
US20120148535A1 (en) 2012-06-14
RU2536931C2 (ru) 2014-12-27
RU2011149458A (ru) 2013-06-27
US10316065B2 (en) 2019-06-11
ES2600955T5 (en) 2025-10-02
PL2428229T5 (pl) 2025-08-18
ES2385251B1 (es) 2013-05-06
CN107252438A (zh) 2017-10-17
CA2761183C (en) 2019-03-26
EP2428229A1 (en) 2012-03-14
ES2600955T3 (es) 2017-02-13
CN102548584A (zh) 2012-07-04
HK1244679A1 (zh) 2018-08-17
FI2428229T4 (fi) 2025-07-29
AU2010244348B2 (en) 2016-08-11
EP2428229B1 (en) 2016-08-03
JP2012525833A (ja) 2012-10-25
US12129280B2 (en) 2024-10-29

Similar Documents

Publication Publication Date Title
Sloane et al. Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
Wallace The polyamines: past, present and future
Linowiecka et al. Melatonin: a potential regulator of DNA methylation
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
AR084938A1 (es) Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
JOP20130273B1 (ar) مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
CU20100216A7 (es) Polipéptidos derivados de la il-2 con actividad agonista y mayor eficacia para la terapia del cáncer e infecciones crónicas
BR112014031788A2 (pt) composições e métodos para o tratamento de diabetes
BRPI0819152B8 (pt) composição farmacêutica tópica
BR112015002357A2 (pt) compostos e composições ativadores de enzimas
Yu et al. Insights into the pathogenesis and treatment of chemotherapy-induced neuropathy: A focus on oxidative stress and neuroinflammation
JOP20230173A1 (ar) أشطر إطالة العمر-النصفي وطرق استخدامها
Gao et al. Synthesis and biological evaluation of the codrug of Leonurine and Aspirin as cardioprotective agents
BRPI0417616A (pt) carboxamidas opticamente ativas e seu uso para o combate de microorganismos indesejáveis
CL2015003267A1 (es) Tratamiento eficaz de nsclc y marcador clínico predictivo de la respuesta de un tumor a un tratamiento.
Mangoni et al. Secondary Metabolites and Peptides as Unique Natural Reservoirs of New Therapeutic Leads for Treatment of Cancer and Microbial Infections
Sánchez-Romero et al. Biobancos, laboratorios clínicos e investigación biomédica
Guéry et al. New role for antigen-presenting activated pDCs in promoting Th17 cells and impacting antitumor immunity
HE Research Progress of siRNA Drugs
Almeida Structural Characterization and Identification of Novel Inhibitors of Respiratory Proteins from Human Bacterial Pathogens
Anikeeva et al. Formal and non-formal education in enhancing the well-being and security of older adults
Cheng Prion diseases: a review.
Bhati-Kushwaha et al. Applications of Nanotechnology in the Field of Medicine

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELL

Effective date: 20120220

FG2A Definitive protection

Ref document number: 2385251

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20130506

FD2A Announcement of lapse in spain

Effective date: 20210915